Ribociclib Approval Extended to Early Breast Cancer In September, the FDA approved ribociclib (Kisqali) in combination with ...
Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...
In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...
Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.
What if we would have watched it for six months? Like, I possibly couldn’t be here talking to you and have lived my life six ...
Q3 2024 Earnings Call Transcript October 29, 2024 Novartis AG beats earnings expectations. Reported EPS is $2.06, expectations were $1.96. Operator: Good morning and good afternoon, and welcome to the ...
Entresto Sales Growth: 26% increase in Q3. Cosentyx Sales Growth: 28% increase, with 38% growth in the US. Kisqali Sales ...
Novartis reports strong Q3 earnings but faces investor concerns over revenue adjustment and pipeline uncertainties. Learn more about NVS stock here.
And we also had important innovation highlights, which we'll talk about a bit more over the course of the call; Kisqali's FDA approval and CHMP positive opinion in hormone receptor positive HER2 ...
Meanwhile, Novartis has gained two new FDA approvals in the US for its breast cancer drug Kisqali and Fabhalta which is used ...
On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), ...
Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...